2020年9月19日～21日に完全にバーチャルで開催された 2020年 欧州臨床腫瘍学会学術集会（ESMO Virtual Congress 2020）より、上部消化菅、肝胆膵の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。
Nivolumab (NIVO) Plus Chemotherapy (Chemo) Versus Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): First Results of the CheckMate 649 Study
Markus Moehler, et al.
Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Patients with Previously Untreated Advanced or Recurrent Gastric/Gastroesophageal Junction (G/GEJ) Cancer: ATTRACTION-4 (ONO-4538-37) Study
Narikazu Boku, et al.
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients with Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study
Ken Kato, et al.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (EC/GEJC) Following Neoadjuvant Chemoradiation Therapy (CRT): First Results of the CheckMate 577 Study
Ronan J. Kelly, et al.
The Canadian Cancer Trials Group PA.7 Trial: Results of a Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Daniel J. Renouf, et al.